WG
TVTX icon

Winton Group’s Travere Therapeutics TVTX Stock Holding History

Winton Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-97,069
Closed -$1.79M – 1510
2020
Q3 		$1.79M Sell
97,069
-19,448
-17% -$378K 0.06% 580
2020
Q2 		$2.38M Buy
116,517
+85,295
+273% +$1.36M 0.06% 563
2020
Q1 		$456K Sell
31,222
-54,934
-64% -$827K 0.01% 1058
2019
Q4 		$1.22M Buy
+86,156
New +$1.1M 0.02% 991

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Winton Group's TVTX Position: Q4 2020 in Review

Winton Group sold out of Travere Therapeutics (TVTX) in Q4 2020, closing a stake of 97,069 shares — an estimated $1.79M sold.

Winton Group first reported a position in TVTX in Q4 2019 and held it in 4 quarters. The position peaked at $2.38M in Q2 2020. 138 funds tracked by Wall St. Rank hold TVTX as of Q4 2020.

  • Winton Group reported no remaining Travere Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Winton Group sold 97,069 Travere Therapeutics shares in Q4 2020, an estimated $1.79M.
  • Winton Group first reported a position in Travere Therapeutics in Q4 2019 and held it in 4 quarters.
  • Winton Group's Travere Therapeutics position peaked at $2.38M in Q2 2020.
  • 138 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2020.

Based on Winton Group's 13F filing for Q4 2020, filed 12 Feb 2021.